Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10450 participants.

Also called NCT07157774

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 10,450 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07157774
  • EU CT 2025-521067-13-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Singapore, Slovakia, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07157774. Randomized; double masking; primary purpose treatment. Start 2025-09-02 (actual); primary completion 2031-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Acronym
MOVE-Lp(a)
Condition
Elevated Lp(a)
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention (Drug)
Muvalaplin
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07157774
Content hash
08aa74430c2cfebc6bcafd64130a38b75cae52169a700d1cff259976c68c6bfd